For most of 2024 and 2025, CagriSema was the most-watched investigational obesity compound in metabolic medicine. The question was whether adding amylin to GLP-1 (Novo Nordisk's approach) would prove superior to adding GIP to GLP-1 (Eli Lilly's tirzepatide approach). In February 2026 that question got an answer, and it wasn't the one Novo Nordisk was hoping for: REDEFINE 4, the head-to-head against tirzepatide, missed its primary endpoint. CagriSema came in second.
That's the honest frame I want to start from. CagriSema is a real compound with real biology and a real strength — but it isn't the next-frontier obesity drug Novo Nordisk positioned it as. I want to walk through what the REDEFINE program actually showed, why REIMAGINE 2 in type 2 diabetes is where the data is genuinely impressive, and where CagriSema actually lands now in the metabolic medicine landscape.
For where CagriSema fits in the broader GLP-1 class, see the GLP-1 peptides class guide. This deep dive stays focused on the cagrilintide + semaglutide combination, the amylin biology that makes it interesting, and the REDEFINE and REIMAGINE program readouts.
CagriSema pairs cagrilintide — a long-acting amylin analogue — with semaglutide 2.4 mg in a single weekly injection. REDEFINE 1, in obesity without diabetes over 68 weeks, came in at roughly 22.7% body weight loss versus 15.8% for semaglutide alone. That's meaningful and confirms the amylin half is doing real work. REDEFINE 4, the head-to-head against Zepbound over 84 weeks, came in at 23.0% versus Zepbound's 25.5% — missing the primary endpoint of non-inferiority. And REIMAGINE 2, in type 2 diabetes against Ozempic over 68 weeks, came in at 14.2% versus 10.2% on weight loss plus a better HbA1c reduction — and that one is where the amylin biology most clearly earns its place in the combination. Novo Nordisk filed an FDA New Drug Application on December 18, 2025; the first regulatory decision is expected late 2026.
The satiety hormone you should know about
Amylin is a 37-amino acid peptide hormone that is co-secreted with insulin from the beta cells of your pancreas after meals. Every time you eat and your pancreas releases insulin, it simultaneously releases amylin. This co-secretion is not coincidental — amylin and insulin work as a coordinated system to manage the postprandial metabolic response.
What amylin does is elegant: it slows gastric emptying, suppresses postprandial glucagon secretion, and — this is the key part — it signals satiety through the central nervous system. Amylin crosses the blood-brain barrier and binds to receptors in the area postrema and the lateral parabrachial nucleus, brain regions that process visceral signals related to fullness and meal termination.
Here's what makes this interesting in the context of GLP-1 therapies: GLP-1 and amylin reduce appetite through overlapping but distinct neural circuits. GLP-1 receptor agonists primarily act on the hypothalamic arcuate nucleus and brainstem nuclei — different anatomical targets from amylin's primary sites of action. They're both telling your brain "you've had enough," but they're sending that message through different phone lines.
This is a critical distinction. When two signals converge on the same outcome through independent pathways, the combined effect has the potential to be more than additive. It's the same principle behind combining GHRH with GHRP for growth hormone release — two different receptor systems amplifying a single biological response.
Why amylin biology matters for metabolic medicine
There's a detail about amylin that often gets overlooked: in people with type 2 diabetes, amylin secretion is impaired alongside insulin secretion. As beta cell function deteriorates, you lose both hormones. The metabolic dysfunction in type 2 diabetes isn't just about insulin — it's simultaneously about losing a key satiety signal.
Pramlintide (brand name Symlin) was actually the first amylin analogue approved for clinical use, way back in 2005, for use alongside insulin in diabetes management. But pramlintide required multiple daily injections and had a short duration of action, which limited its practical utility. The science was solid; the pharmacokinetics weren't ideal.
Cagrilintide is Novo Nordisk's long-acting amylin analogue. It has a significantly extended half-life compared to pramlintide, allowing for once-weekly dosing. As a standalone compound, cagrilintide showed approximately 10-11% body weight reduction over 26 weeks in Phase 2 data. That's impressive for a single agent, but it was the combination data that really turned heads.
The combination approach
CagriSema is a fixed-ratio co-formulation of cagrilintide and semaglutide 2.4mg (the same dose used in Wegovy). Take the most proven GLP-1 agonist and combine it with a long-acting amylin analogue in a single weekly injection.
The biological rationale is sound. Semaglutide activates GLP-1 receptors in the hypothalamus, reducing appetite through POMC/CART neuron activation and NPY/AgRP neuron inhibition. Cagrilintide activates amylin receptors in the area postrema and hindbrain, triggering a separate but complementary satiety cascade. Together, you're modulating appetite at multiple levels of the central nervous system simultaneously.
There's also a metabolic component beyond appetite. Amylin receptor activation has been shown to increase energy expenditure in preclinical models, potentially through brown adipose tissue activation. GLP-1 improves insulin sensitivity and reduces hepatic glucose output. The metabolic effects are complementary in ways that go beyond simply eating less.
The research community has referenced this combination formulation at standard clinical concentrations, consistent with the dosing used across the REDEFINE trial program.
REDEFINE 1: the data that changed the conversation
The REDEFINE 1 trial was the Phase 3 study that put CagriSema on the map. It enrolled approximately 3,400 adults with obesity (BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity) but without type 2 diabetes. The trial ran for 68 weeks and compared CagriSema against semaglutide 2.4mg alone, cagrilintide alone, and placebo.
The headline: participants on CagriSema lost approximately 22.7% of their body weight at 68 weeks. The semaglutide-alone arm lost approximately 15.8%, and the cagrilintide-alone arm lost approximately 8.6%.
The absolute magnitude is striking. Roughly 23% body weight loss from a pharmacological intervention puts CagriSema in the same territory as the most effective metabolic interventions we have, approaching the range historically seen only with bariatric surgery.
Then there's the delta over semaglutide alone. CagriSema produced approximately 7 percentage points more weight loss than semaglutide 2.4mg, which is already one of the most effective weight loss agents ever studied. That incremental benefit — roughly 40-45% more weight loss than semaglutide alone — is directly attributable to the amylin pathway. This is not a minor add-on effect.
A meaningful proportion of CagriSema-treated participants achieved 25% or greater total body weight loss. In the GLP-1 field, we've learned that the proportion of "super-responders" is often more clinically relevant than the mean, because it tells you about the ceiling of what the compound can do when biology and adherence align.
Cagrilintide as a standalone
Before CagriSema, cagrilintide was studied as a standalone agent, and those results are worth understanding because they isolate the amylin effect.
A Phase 2 trial published in The Lancet evaluated cagrilintide at multiple doses in adults with overweight or obesity. At the highest dose over 26 weeks, participants lost approximately 10.8% of body weight — significantly more than placebo. The dose-response curve was clear and the safety profile was manageable, with gastrointestinal side effects being the most common.
What this data tells us about amylin as a weight loss mechanism is significant. A 10-11% weight loss from a single amylin analogue — without any GLP-1 component — demonstrates that amylin signaling is a legitimate, independent pathway for appetite regulation. This isn't just riding on the coattails of GLP-1 science. Amylin has its own story.
The standalone data also suggests that the additional weight loss seen with CagriSema versus semaglutide alone is genuinely attributable to the amylin mechanism, not some pharmacokinetic interaction or formulation artifact. Two pathways, each with independent efficacy, combined for an enhanced result.
The REDEFINE and REIMAGINE program: what the readouts showed
CagriSema is being tested across two parallel Phase 3 programs. The REDEFINE program covers obesity populations; the REIMAGINE program covers type 2 diabetes. Three major readouts now define what the compound can and can't do.
REDEFINE 1: obesity without diabetes (already covered above)
CagriSema 22.7% body weight loss versus semaglutide 15.8% at 68 weeks. This is the trial that established the amylin combination's basic premise — adding cagrilintide to semaglutide produces roughly 7 percentage points more weight loss than semaglutide alone. The biological logic of two independent satiety pathways converging on the same outcome holds.
REIMAGINE 2: type 2 diabetes vs Ozempic — where CagriSema actually shines
REIMAGINE 2 read out in February 2026, and it's the trial where CagriSema's mechanism most clearly earns its keep. It put CagriSema 2.4mg/2.4mg up against semaglutide (Ozempic) at multiple dose levels in adults with type 2 diabetes over 68 weeks. CagriSema produced 14.2% weight loss against Ozempic's 10.2% — and a better HbA1c reduction on top of that, 1.91% versus 1.76%.
The mechanistic story here is clean. In type 2 diabetes, endogenous amylin secretion is impaired alongside insulin — the pancreatic beta cells lose both signaling outputs in parallel. Restoring the amylin signal in a population that's specifically deficient in it produces measurably better outcomes than GLP-1 alone. This is the place where the amylin-plus-GLP-1 combination has the cleanest biological argument and the strongest data backing it.
REDEFINE 4: the head-to-head against tirzepatide that missed
REDEFINE 4 — the trial that was supposed to settle whether GLP-1+amylin or GLP-1+GIP was the better way to combine receptors for obesity — also read out in February 2026. It didn't go the way Novo Nordisk wanted. CagriSema 2.4mg came in at 23.0% body weight loss versus Zepbound 15mg's 25.5% over 84 weeks. The primary endpoint was non-inferiority on weight loss, and the trial didn't hit it. When the analysis used the more conservative read that accounts for people who dropped out or stopped taking the drug, the gap stayed the same shape: CagriSema 20.2% versus Zepbound 23.6%.
Reporting from STAT News, BioSpace, and Clinical Trials Arena framed the result bluntly: the compound that was positioned as the next frontier in obesity pharmacotherapy fell short of the current standard. Tirzepatide is more effective for weight loss in obesity without diabetes. That's the honest read of the data.
Regulatory timing
Novo Nordisk filed the FDA New Drug Application for CagriSema on December 18, 2025 — based mostly on the REDEFINE 1 data, since REDEFINE 4 hadn't read out yet. The filing is for the 2.4mg/2.4mg fixed-dose combination for chronic weight management. The FDA's first regulatory decision is expected late 2026, and approvals in other major markets would follow on a similar timeline if the submissions hold up.
The pharmaceutical strategy is now clearer than it was a year ago: CagriSema enters the market as a real second option in the next-generation obesity space, not as the new standard. For some patient populations — particularly type 2 diabetes — the data argues it may be the better choice. For obesity without diabetes, tirzepatide retains the head-to-head advantage.
The amylin biology is genuinely separate
It's worth being precise about what's different here, separate from the head-to-head outcome. The amylin pathway is not a variation of GLP-1 signaling — it's a structurally and mechanistically distinct endocrine system.
Amylin receptors are calcitonin receptors complexed with receptor activity-modifying proteins (RAMPs). They have a completely different molecular structure from GLP-1 receptors. They're expressed in different brain regions (notably the area postrema and lateral parabrachial nucleus). They activate different intracellular signaling cascades. The combination of GLP-1 and amylin agonism engages two independent satiety circuits converging on a shared behavioral outcome.
That biology is real and worth understanding even when the head-to-head data didn't fall the way Novo Nordisk hoped. REDEFINE 4 told us that GLP-1+amylin is not superior to GLP-1+GIP for obesity weight loss alone. It didn't tell us that the amylin pathway is irrelevant or that the combination has no role — it told us about one specific patient population (obesity without diabetes) at one specific dose comparison. The REIMAGINE 2 result in T2D points to where the amylin mechanism appears to add real value: in populations where endogenous amylin is depleted.
The way the landscape sorts out now is into three distinct strategies, each represented by one of the next-generation compounds. The incretin route — combining GLP-1 with GIP — is what tirzepatide does. The energy expenditure route — adding glucagon receptor activation — is what retatrutide is testing. The satiety augmentation route — adding amylin to GLP-1 — is what CagriSema is. Each one is pulling a different lever. None of them is universally better than the others. The next decade in this space is probably going to look less like one drug winning and more like matching the right mechanism to the right patient's metabolic profile.
Side effects and tolerability
The gastrointestinal side effect profile is generally consistent with what's expected from GLP-1 therapy: nausea, vomiting, and diarrhea, primarily during dose escalation. The combination doesn't appear to dramatically worsen GI tolerability compared to semaglutide alone, which is an important practical consideration. Amylin's gastric emptying effects are mechanistically similar to GLP-1's, so the overlap in side effects is expected rather than additive.
The REDEFINE program has not surfaced unexpected safety signals beyond what the individual components — semaglutide and cagrilintide — were already understood to produce. Injection site irritation rates appear slightly higher with the combination than with semaglutide alone, which is noted in the REIMAGINE 2 trial reporting. The once-weekly injection format mirrors existing semaglutide dosing.
Where CagriSema actually lands
The honest read on CagriSema after the 2026 readouts is that it's a real second-line option in next-generation obesity pharmacotherapy, with a particular strength in type 2 diabetes. It isn't the standard. Tirzepatide remains the most effective single-compound option for weight loss in obesity, confirmed by both SURMOUNT-5 (vs semaglutide) and REDEFINE 4 (vs CagriSema).
What CagriSema offers is a mechanistically different option for patients where the amylin pathway has independent value. REIMAGINE 2 makes the clearest case: in type 2 diabetes, where endogenous amylin secretion is impaired alongside insulin, restoring that signal produces both weight and glycemic outcomes superior to GLP-1 alone. That's a real clinical benefit for a real patient population.
The broader pattern that emerged from 2025-2026 is that adding receptors to GLP-1 keeps producing better results, but the magnitude of additional benefit depends on which receptor you add and what patient population you're treating. GIP+GLP-1 (tirzepatide) is more effective than amylin+GLP-1 (CagriSema) for obesity weight loss specifically. Glucagon+GIP+GLP-1 (retatrutide) is the highest-magnitude early-stage signal in the field. CagriSema occupies a real but more specific niche than the original "next frontier" positioning suggested.
Frequently asked questions
What exactly is CagriSema?
CagriSema is a combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist) in a single once-weekly injection. It targets two distinct satiety pathways — amylin receptors in the hindbrain and GLP-1 receptors in the hypothalamus — rather than relying on GLP-1 signaling alone. This dual-pathway approach produced approximately 23% weight loss in the REDEFINE 1 trial, exceeding what semaglutide achieved as a single agent.
Why should I care about amylin?
Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells after meals. It promotes satiety by acting on receptors in the area postrema and lateral parabrachial nucleus, slows gastric emptying, and suppresses postprandial glucagon. It represents a satiety pathway independent from GLP-1, meaning it can reduce appetite through mechanisms that GLP-1 alone doesn't fully engage. In people with type 2 diabetes, amylin secretion is impaired, making its replacement especially relevant.
How does it stack up against tirzepatide and retatrutide?
The head-to-head data now exists. REDEFINE 4 (Feb 2026) compared CagriSema directly against tirzepatide (Zepbound) in adults with obesity over 84 weeks. CagriSema produced 23.0% weight loss; Zepbound produced 25.5%. The trial's primary endpoint of non-inferiority was not achieved — tirzepatide proved meaningfully more effective for weight loss in obesity. Retatrutide hasn't been directly compared to CagriSema, but Phase 2 retatrutide reported 24.2% weight loss in 48 weeks (shorter timeframe), suggesting it's at least competitive with tirzepatide and possibly better. The honest summary: CagriSema is the third-place option among the next-generation compounds for weight loss in obesity, with the caveat that REIMAGINE 2 (T2D head-to-head vs Ozempic) is the trial where CagriSema's mechanism has its clearest win. For the full class comparison, see the GLP-1 peptides class guide.
What did REDEFINE 1 actually show?
REDEFINE 1 enrolled approximately 3,400 adults with obesity and found that CagriSema produced approximately 22.7% body weight loss at 68 weeks, compared to 15.8% for semaglutide alone, 8.6% for cagrilintide alone, and 2.3% for placebo. The safety profile was generally consistent with existing GLP-1 therapies, with gastrointestinal symptoms being the most common side effects.
Can I get CagriSema now?
Not yet, but the regulatory pathway is in motion. Novo Nordisk filed a New Drug Application with the FDA on December 18, 2025, based primarily on the REDEFINE 1 obesity data. The first regulatory decision is expected in late 2026. If approved, CagriSema would launch as a fixed-dose 2.4mg/2.4mg combination for chronic weight management in adults with obesity, with type 2 diabetes indications likely following based on REIMAGINE 2 results. Approval in other major markets (EU, UK) would follow on a similar timeline if the submissions hold up.
Will CagriSema fix the weight regain problem?
This is one of the most important open questions in metabolic medicine. Current data on GLP-1 monotherapy suggests that weight tends to return after discontinuation. Whether CagriSema's dual-pathway approach provides more durable weight maintenance is not yet established — this will require longer-term data beyond the initial 68-week trial period. The biological hypothesis is that engaging more satiety pathways could lead to a more sustained metabolic reset, but this remains to be demonstrated.
Related Reading
Read more: What are peptides? A science-first primer